Thomas E. Griffin

Tom Griffin joined Nuvaira in January 2020, bringing with him more than 30 years of finance experience and a background leading several medical device companies in multiple venture financings and initial public offerings including success in rapid commercialization and in mergers and acquisitions.

Prior to joining Nuvaira, Tom was most recently Chief Financial Officer of Avedro, Inc. (NASDAQ:AVDR) a leading hybrid ophthalmic pharmaceutical and medical technology company focused on treating corneal disease and disorders and improving vision to reduce dependency on eyeglasses or contact lens. Avedro completed its initial public offering in February 2019 and was acquired by Glaukos Corporation (NYSE:GKOS) in November 2019. Prior to joining Avedro, Mr. Griffin served as the Chief Financial Officer of Entellus Medical, Inc., a medical technology company focused on delivering superior patient and physician experiences through products designed for the minimally invasive treatment of chronic and recurrent sinusitis in both adult and pediatric patients, from 2007 to May 2016, including during Entellus’ initial public offering in 2015, before transitioning to Vice President of Finance from May 2016 to January 2017. Entellus was acquired by Stryker Corporation in February 2018. Tom has also served as Chief Financial Officer and Secretary of Digital Gene Technologies, Inc., a privately held biotechnology company. He was also Controller for Centerpulse Spine-Tech, Inc. (now Zimmer Spine, Inc.) and CIMA Labs Inc. (now owned by Teva Pharmaceutical Industries Ltd.).

Mr. Griffin earned a B.A. in Accounting from the University of Minnesota, Duluth and an M.B.A. in Management from the University of St. Thomas. Mr. Griffin is a certified public accountant (inactive status).